Sugi Predict

Sugi Predict / Compounds / SCHEMBL8907678

SCHEMBL8907678

SCHEMBL8907678

COC(=O)N[C@@H](Cc1cscn1)C(=O)C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.41
▸ CAPN1 P07384 5/20 0.41
▸ CTSK P43235 2/20 0.40
▸ GPR142 Q7Z601 6/20 0.38
▸ FOLH1 Q04609 1/20 0.36
▸ CTSB P07858 1/20 0.36
▸ CTSS P25774 1/20 0.36
▸ CNR2 P34972 1/20 0.35
▸ DPP4 P27487 2/20 0.34
▸ DPP8 Q6V1X1 2/20 0.34
▸ DPP9 Q86TI2 2/20 0.34
▸ KLKB1 P03952 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL756368 0.85 FOLH1 (0.47) SCN9ACAPN1CTSKGPR142FOLH1
SCHEMBL18731295 0.85 FOLH1 (0.47) SCN9ACAPN1CTSKGPR142FOLH1
SCHEMBL14864797 0.85 CTSK (0.42) SCN9ACAPN1CTSKGPR142FOLH1
SCHEMBL14879201 0.85 CNR2 (0.44) SCN9ACAPN1CTSKGPR142FOLH1
SCHEMBL24919850 0.83 CAPN1 (0.41) SCN9ACAPN1CTSKGPR142FOLH1
SCHEMBL888810 0.83 CTSK (0.43) SCN9ACAPN1CTSKGPR142FOLH1
SCHEMBL10122815 0.83 CTSK (0.43) SCN9ACAPN1CTSKGPR142FOLH1
SCHEMBL14886205 0.83 CTSK (0.43) SCN9ACAPN1CTSKGPR142FOLH1
SCHEMBL22803151 0.82 CAPN1 (0.41) SCN9ACAPN1CTSKGPR142FOLH1
SCHEMBL23324594 0.80 SCN9A (0.50) SCN9ACAPN1CTSKCTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752611-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2020-08-25 — — US disclosed
US-8637561-B2 Linked diimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2014-01-28 — — US disclosed
US-20130295049-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS ENANTA PHARMACEUTICALS, INC (US) 2013-11-07 — — US disclosed
US-8188132-B2 Linked dibenzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
US-20100226883-A1 LINKED DIIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-09 — — US disclosed
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226883-A1 LINKED DIIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 SCN9A 3768/4885CAPN1 2299/4885CTSK 2105/4885
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES EIF2AK2, NSUN2, ZC3HAV1 SCN9A 4519/4885CAPN1 3134/4885CTSK 2467/4885
US-20130295049-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS EIF2AK2, ZC3HAV1, NSUN2 SCN9A 4655/4885CAPN1 3110/4885CTSK 2268/4885
US-10752611-B2 Benzimidazole derivatives EIF2AK2, ZC3HAV1, ZC3HAV1L SCN9A 4589/4885CAPN1 2642/4885CTSK 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.